Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardio amyloid-artificial intelligence: advanced multi-modal screening for transthyretin cardiac amyloidosis in severe aortic stenosis patients.

European heart journal. Digital health·2026
Same author

Deprescribing in Patients With Cardiovascular Disease Experiencing Polypharmacy: A Scientific Statement From the American Heart Association.

Circulation·2026
Same author

Neighborhood-Level Socially Determined Vulnerabilities and Outcomes After Heart Failure Hospitalization.

Journal of the American Heart Association·2026
Same author

Identification of Potentially Inappropriate Medications for Adults Below 65 Years: Protocol for a Modified Delphi Study.

JMIR research protocols·2026
Same author

Targeting macrophage ferritin heavy chain mitigates ferroptosis and lung injury in experimental acute respiratory distress syndrome.

Nature communications·2026
Same author

Association between depressive symptoms and physical function among participants with heart disease in the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study.

medRxiv : the preprint server for health sciences·2026

Related Experiment Video

Updated: Jun 20, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

Beta-Blocker Discontinuation in Acute Heart Failure: A Systematic Review and Meta-Analysis.

Nima Alaeiilkhchi1, Wade Thompson1, Lisa M McCarthy2

  • 1Faculty of Medicine, Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, Canada.

JACC. Advances
|June 18, 2026
PubMed
Summary

Discontinuing beta-blockers during acute decompensated heart failure (ADHF) hospitalization shows uncertain effects on mortality. Evidence is of very low certainty, suggesting potential harm may be due to confounding factors, not direct causation.

Keywords:
acute decompensated heart failurebeta-blockerscontinuationdiscontinuationmortalitysystematic review

Related Experiment Videos

Last Updated: Jun 20, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

Area of Science:

  • Cardiology
  • Clinical Pharmacology
  • Evidence Synthesis

Background:

  • The management of acute decompensated heart failure (ADHF) often involves decisions regarding beta-blocker therapy.
  • Uncertainty exists regarding the optimal strategy for beta-blocker use during ADHF hospitalization.

Purpose of the Study:

  • To systematically review and synthesize evidence on the continuation versus discontinuation of beta-blockers during ADHF hospitalization.
  • To assess the impact of beta-blocker management on in-hospital and short-term mortality, and rehospitalization rates.

Main Methods:

  • Systematic search of MEDLINE, Embase, and CENTRAL databases.
  • Inclusion of randomized controlled trials and observational cohort studies comparing beta-blocker discontinuation with continuation in ADHF.
  • Meta-analysis of observational studies using random-effects models, prioritizing adjusted estimates.

Main Results:

  • Thirteen studies (1 RCT, 12 cohort studies) were included.
  • In-hospital mortality risk associated with discontinuation was uncertain (pooled OR: 5.20; very low certainty).
  • Short-term discontinuation may be linked to higher mortality up to 3 months (pooled HR: 2.30; low certainty); rehospitalization data were inconsistent.

Conclusions:

  • Current evidence on beta-blocker discontinuation in ADHF is of very low certainty.
  • Observed potential harm might stem from confounding by indication or delayed restart, rather than direct causal effects.
  • High-quality randomized controlled trials and nonrandomized studies are needed to clarify the risks and benefits.